Results 31 to 40 of about 13,346 (214)

Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA [PDF]

Journal of Immunological Methods, 2011
Two assay methods for quantification of the disialoganglioside (GD2)-specific binding activities of anti-GD2 monoclonal antibodies and antibody immunofusion proteins, such as ch14.18 and hu14.18-IL2, were developed. The methods differed in the use of either microtiter plates coated with purified GD2 or plates seeded with GD2-expressing cell lines to ...
Gopalan, Soman, Xiaoyi, Yang, Hengguang, Jiang, Steve, Giardina, Gautam, Mitra   +4 more
openaire   +2 more sources

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics

Molecular Therapy: Nucleic Acids, 2021
Because current mainstream anti-glycolipid GD2 therapeutics for neuroblastoma (NB) have limitations, such as severe adverse effects, improved therapeutics are needed. In this study, we developed a GD2 aptamer (DB99) and constructed a GD2-aptamer-mediated
Liyu Zhang, Meng Wang, Zeen Zhu, Shengquan Chen, Haibin Wu, Ying Yang, Fengyu Che, Qiao Li, Hui Li   +8 more
doaj   +1 more source

A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs. [PDF]

PLoS ONE, 2014
We recently constructed a novel non-replicating dominant-negative HSV-2 recombinant viral vaccine (CJ2-gD2) capable of expressing various HSV-2 antigens that are dominant targets of HSV-2-specific CD8 T-cell response.
Pengwei Zhang, Lining Xie, John W Balliet, Danilo R Casimiro, Feng Yao   +4 more
doaj   +1 more source

Anti-GD2 immunotherapy for neuroblastoma [PDF]

Expert Review of Anticancer Therapy, 2017
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents.
Sameer, Sait, Shakeel, Modak
openaire   +2 more sources

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells

OncoImmunology, 2020
Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression
Christian M. Seitz, Sarah Schroeder, Philipp Knopf, Ann-Christin Krahl, Jana Hau, Sabine Schleicher, Manuela Martella, Leticia Quintanilla-Martinez, Manfred Kneilling, Bernd Pichler, Peter Lang, Daniel Atar, Karin Schilbach, Rupert Handgretinger, Patrick Schlegel   +14 more
doaj   +1 more source

IMMU-55. GD2 IS A MACROPHAGE CHECKPOINT MOLECULE AND COMBINED GD2/CD47 BLOCKADE RESULTS IN SYNERGISTIC EFFECTS AGAINST GD2 POSITIVE MALIGNANCIES [PDF]

Neuro-Oncology, 2020
Abstract GD2 is a disialoganglioside expressed on a variety of tumors including DIPG, neuroblastoma and osteosarcoma. Anti-GD2 antibodies have demonstrated some success in neuroblastoma and they have either not proven to be effective or have not been evaluated in other GD2 positive malignancies. CD47 is the dominant “Don’t Eat Me” signal
Johanna Theruvath, Christopher Mount, Michelle Monje, Crystal Mackall, Robbie Majzner   +4 more
openaire   +1 more source

GD2-Targeted Immunotherapy and Radioimmunotherapy [PDF]

Seminars in Oncology, 2014
Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. They include pediatric embryonal tumors (neuroblastoma, retinoblastoma, brain tumors, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma), as well as adult cancers (small cell lung cancer, melanoma, soft tissue sarcomas).
Konstantin, Dobrenkov, Nai-Kong V, Cheung   +1 more
openaire   +2 more sources

Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas [PDF]

Medical Journal of The Islamic Republic of Iran, 2021
Background: GD2 synthase (GD2S) is the key enzyme required for ganglioside GD2 synthesis. It is commonly expressed in normal tissues and various cancers. Ganglioside GD2 is identified as a breast cancer stem cells (BCSCs) marker that promotes tumorigenesis.
Mansoori, Maryam, Mirzaei, Alireza, Abdi Rad, Isa, Mahmodlou, Rahim, Mansouri, Fatemeh, Saeednejad Zanjani, Leili, Asadi- Lari, Zeynab, Madjd, Zahra   +7 more
openaire   +2 more sources

Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency

Cancer Reports, 2021
Background Chimeric antigen receptor (CAR) T‐cell therapy of pediatric sarcomas is challenged by the paucity of targetable cell surface antigens. A candidate target in osteosarcoma (OS) is the ganglioside GD2, but heterogeneous expression of GD2 limits ...
Malena Wiebel, Sareetha Kailayangiri, Bianca Altvater, Jutta Meltzer, Kay Grobe, Sabine Kupich, Claudia Rossig   +6 more
doaj   +1 more source

GD2 synthase [PDF]

Cancer, 2001
Neuroblastomas (NBs) almost ubiquitously express the ganglioside GD2. GD2 synthesis is dependent on the key enzyme GD2 synthase. Thus, GD2 synthase transcript may prove to be a potential molecular marker of NB.Seventy-seven NB tumor tissues of all stages, 5 NB cell lines, and 26 normal bone marrows (BMs) and peripheral blood (PBL) samples, as well as ...
M S, Lo Piccolo, N K, Cheung, I Y, Cheung   +2 more
openaire   +2 more sources